Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Dyspnea and Exercise Tolerance in COPD
NCT03679312Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Sep 2018
- Primary completion
- Nov 2023
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of nitric oxide in chronic obstructive pulmonary disease (COPD), sponsored by University of Alberta. Started Sep 2018; status: completed.
02
Drugs
nitric oxide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03679312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679312.